Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants

CONTEXT: Familial partial lipodystrophy (FPLD) is most commonly caused by pathogenic variants in LMNA and PPARG. Leptin replacement with metreleptin has largely been studied in the LMNA group. OBJECTIVE: To understand the efficacy of metreleptin in PPARG vs LMNA pathogenic variants and investigate p...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Endocrinol Metab
Egile Nagusiak: Sekizkardes, Hilal, Cochran, Elaine, Malandrino, Noemi, Garg, Abhimanyu, Brown, Rebecca J
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Endocrine Society 2019
Gaiak:
Clinical Research Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6563798/
https://ncbi.nlm.nih.gov/pubmed/31194872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2018-02787
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak